Skip to content

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3xCD20 bispecific T-cell engagers

  • Date Published

    March 21, 2026

Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Muller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VKJ, Poeck H et al. Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3xCD20 bispecific T-cell engagers. Blood Adv. 2026 Mar 10. 10:1675–1686. doi:10.1182/bloodadvances.2025017766. PMID: 41124666